Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Follow-Up Questions
Liquidia Corp 的 CEO 是誰？
Dr. Roger Jeffs 是 Liquidia Corp 的 Chief Executive Officer，自 2020 加入公司。
LQDA 股票的價格表現如何？
LQDA 的當前價格為 $23.22，在上個交易日 increased 了 3.29%。
Liquidia Corp 的主要業務主題或行業是什麼？
Liquidia Corp 屬於 Pharmaceuticals 行業，該板塊是 Health Care
